Two phase II clinical trials with the GSK‐3β inhibitor, Tideglusib, showed no clinical benefits in Alzheimer's disease (Lovestone et al, 2015) and progressive supranuclear palsy (Tolosa et al, 2014). The gene discussed is GSK3B; the disease is early-onset autosomal dominant Alzheimer disease.